9-34649466-C-T
Position:
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PP3_StrongPP5_Very_Strong
The NM_000155.4(GALT):c.961C>T(p.His321Tyr) variant causes a missense change. The variant allele was found at a frequency of 0.0000031 in 1,614,056 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: 𝑓 0.000013 ( 0 hom., cov: 31)
Exomes 𝑓: 0.0000021 ( 0 hom. )
Consequence
GALT
NM_000155.4 missense
NM_000155.4 missense
Scores
13
4
2
Clinical Significance
Conservation
PhyloP100: 4.13
Genes affected
GALT (HGNC:4135): (galactose-1-phosphate uridylyltransferase) Galactose-1-phosphate uridyl transferase (GALT) catalyzes the second step of the Leloir pathway of galactose metabolism, namely the conversion of UDP-glucose + galactose-1-phosphate to glucose-1-phosphate + UDP-galactose. The absence of this enzyme results in classic galactosemia in humans and can be fatal in the newborn period if lactose is not removed from the diet. The pathophysiology of galactosemia has not been clearly defined. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2012]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 16 ACMG points.
PM1
In a hotspot region, there are 7 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 4 uncertain in NM_000155.4
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.97
PP5
Variant 9-34649466-C-T is Pathogenic according to our data. Variant chr9-34649466-C-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 25299.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
GALT | NM_000155.4 | c.961C>T | p.His321Tyr | missense_variant | 10/11 | ENST00000378842.8 | |
GALT | NM_001258332.2 | c.634C>T | p.His212Tyr | missense_variant | 8/9 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
GALT | ENST00000378842.8 | c.961C>T | p.His321Tyr | missense_variant | 10/11 | 1 | NM_000155.4 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152186Hom.: 0 Cov.: 31
GnomAD3 genomes
AF:
AC:
2
AN:
152186
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00000795 AC: 2AN: 251458Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135902
GnomAD3 exomes
AF:
AC:
2
AN:
251458
Hom.:
AF XY:
AC XY:
2
AN XY:
135902
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000205 AC: 3AN: 1461870Hom.: 0 Cov.: 31 AF XY: 0.00000138 AC XY: 1AN XY: 727238
GnomAD4 exome
AF:
AC:
3
AN:
1461870
Hom.:
Cov.:
31
AF XY:
AC XY:
1
AN XY:
727238
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152186Hom.: 0 Cov.: 31 AF XY: 0.0000134 AC XY: 1AN XY: 74358
GnomAD4 genome
AF:
AC:
2
AN:
152186
Hom.:
Cov.:
31
AF XY:
AC XY:
1
AN XY:
74358
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
ExAC
AF:
AC:
1
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:6Uncertain:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase Pathogenic:4Uncertain:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 18, 2024 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Jun 05, 2021 | The GALT c.961C>T; p.His321Tyr variant (rs367543266) is reported in the literature in one compound heterozygote and one homozygote affected with galactosemia (Webb 2003, ARUP data). This variant is reported in ClinVar (Variation ID: 25299). This variant is only observed on two alleles in the Genome Aggregation Database, indicating it is not a common polymorphism. The histidine at codon 321 is moderately conserved, and computational analyses predict that this variant is deleterious (REVEL: 0.922). Based on available information, this variant is considered to be likely pathogenic. References: Webb AL et al. Verbal dyspraxia and galactosemia. Pediatr Res. 2003 Mar;53(3):396-402. PMID: 12595586. - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jul 17, 2024 | Variant summary: GALT c.961C>T (p.His321Tyr) results in a conservative amino acid change located in the Galactose-1-phosphate uridyl transferase, C-terminal domain (IPR005850) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 8e-06 in 251458 control chromosomes (gnomAD). c.961C>T has been reported in the literature in individuals affected with Galactosemia including homozygous individuals with classic galactosemia (example: Webb_2003, Mir_2022, Yuzyuk_2018). These data indicate that the variant is very likely to be associated with disease. In vitro and in vivo functional studies show that the variant resulted in reduced activity (Yuzyuk_2018). The following publications have been ascertained in the context of this evaluation (PMID: 12595586, 30172461, 27005423). ClinVar contains an entry for this variant (Variation ID: 25299). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 29, 2023 | This sequence change replaces histidine, which is basic and polar, with tyrosine, which is neutral and polar, at codon 321 of the GALT protein (p.His321Tyr). This variant is present in population databases (rs367543266, gnomAD 0.007%). This missense change has been observed in individual(s) with galactosemia (PMID: 12595586, 30172461; Invitae). ClinVar contains an entry for this variant (Variation ID: 25299). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GALT protein function. Experimental studies have shown that this missense change affects GALT function (PMID: 30172461). For these reasons, this variant has been classified as Pathogenic. - |
Uncertain significance, flagged submission | clinical testing | Counsyl | Jan 08, 2018 | - - |
GALT-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Apr 15, 2024 | The GALT c.961C>T variant is predicted to result in the amino acid substitution p.His321Tyr. This variant has been reported, in the homozygous state or heterozygous with a second rare GALT variant, in patients with galactosemia (Table 1, Webb et al. 2003. PubMed ID: 12595586; Table 2, Yuzyuk et al. 2018. PubMed ID: 30172461; Mir et al. 2023. doi: 10.1159/000528905). Additionally, we have observed this variant in the apparent homozygous state in two siblings with classic galactosemia (Internal Data, PreventionGenetics). The p.His321 amino acid has been reported to play a role in GALT enzyme Zn2+ binding, and the p.His321Tyr substitution is predicted to disrupt this metal binding (McCorvie et al. 2016. PubMed ID: 27005423). Additionally, the p.His321Tyr substitution was reported to reduce in vitro enzyme activity to 3.9% of wild-type (Yuzyuk et al. 2018. PubMed ID: 30172461). This variant is reported in 0.0062% of alleles in individuals of African descent in gnomAD. Based on the collective evidence, this variant is interpreted as pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Dec 21, 2022 | PP3, PP4, PM2, PM3, PS3 - |
Galactosemia Uncertain:1
Uncertain significance, flagged submission | clinical testing | Natera, Inc. | Sep 21, 2018 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Pathogenic
.;D
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Pathogenic
D;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D
MetaSVM
Pathogenic
D
MutationAssessor
Pathogenic
.;H
MutationTaster
Benign
D;D
PrimateAI
Pathogenic
D
PROVEAN
Uncertain
D;D
REVEL
Pathogenic
Sift
Benign
T;T
Sift4G
Uncertain
T;T
Polyphen
1.0
.;D
Vest4
MutPred
0.91
.;Gain of catalytic residue at P325 (P = 0.1317);
MVP
MPC
0.35
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at